title: Persistent improvement of cardiovascular risk factors in spontaneously hypertensive rats following early short-term captopril treatment.
abstract: This study was designed to determine whether an improvement in cardiovascular risk factors persists in spontaneously hypertensive rats (SHR) following withdrawal of angiotensin converting enzyme inhibitor (ACE-I) treatment. SHR were given deionized drinking water or captopril solution from four to sixteen weeks of age. At twelve weeks of age, rats from each group were instrumented with radiotelemetry devices for continuous monitoring of blood pressure. Mean arterial blood pressure was significantly lower in captopril-treated SHR during treatment (92+/-2 vs 147+/-1 mm Hg), and at twelve weeks after treatment withdrawal (131+/-2 vs 158+/-2 mm Hg). In addition, proteinuria, renal vascular resistance, plasma triglyceride levels, fasting glucose levels, post-prandial insulin levels, and heart weights were significantly reduced in the treated SHR compared to control SHR, at time-points between three to seven months after captopril withdrawal. Our findings indicate that short-term administration of an ACE-I during the developmental phase of hypertension in the SHR results in a long-term overall improvement of cardiovascular risk factors.
authors.affiliation: Center for Clinical Pharmacology, Department of Medicine, University of Pittsburgh Medical Center, PA 15213-2582, USA. Kost@med1.dept-med.pitt.edu
authors.forename: C K
authors.initials: CK
authors.lastname: Kost
authors.forename: B R
authors.initials: BR
authors.lastname: Rominski
authors.forename: W A
authors.initials: WA
authors.lastname: Herzer
authors.forename: E K
authors.initials: EK
authors.lastname: Jackson
authors.forename: S P
authors.initials: SP
authors.lastname: Tofovic
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D018660:Blood Pressure Monitoring, Ambulatory; D002216:Captopril / Q000627:therapeutic use*; D002319:Cardiovascular System / Q000187:drug effects / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007328:Insulin / Q000097:blood; D008297:Male; D051381:Rats; D011918:Rats, Inbred SHR; D020127:Recovery of Function / Q000187:drug effects*; D012307:Risk Factors; D013686:Telemetry; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D007328:Insulin; D014280:Triglycerides; D002216:Captopril